|
|
Substance Name: Terbinafine [USAN:INN:BAN]
RN: 91161-71-6
UNII: G7RIW8S0XP
InChIKey: DOMXUEMWDBAQBQ-WEVVVXLNSA-N
Note
- A naphthalene derivative that inhibits fungal SQUALENE EPOXIDASE and is used to treat DERMATOMYCOSES of the skin and nails.
Molecular Formula
- C21-H25-N
Molecular Weight
- 291.4355
Classification Codes
- Anti-Infective Agents
- Antifungal
- Antifungal Agents
- Drug / Therapeutic Agent
- Enzyme Inhibitors
- Human Data
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Terbinafine
- Terbinafine [USAN:INN:BAN]
MeSH Heading
- Terbinafine
Synonyms
- (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine
- (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine
- BRN 4256376
- EC 618-706-8
- Lamasil
- Lamisil
- Lamisil AT
- Lamisil Tablet
- SF 86-327
- SF-86-327
- Terbinafine
- UNII-G7RIW8S0XP
Systematic Names
- (2E)-N,6,6-Trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine
- 1-Naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-, (E)-
Registry Numbers
CAS Registry Number
- 91161-71-6
FDA UNII
- G7RIW8S0XP
System Generated Number
- 0091161716
Structure Descriptors
InChI
InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+InChIKey
DOMXUEMWDBAQBQ-WEVVVXLNSA-NSmiles
CN(C\C=C\C#CC(C)Toxicity
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
man | TDLo | oral | 3918ug/kg (3.918mg/kg) | GASTROINTESTINAL: OTHER CHANGES | Kiso to Rinsho. Clinical Report. Vol. 27, Pg. 6087, 1993. |
man | TDLo | oral | 89mg/kg/25D-I (89mg/kg) | LIVER: "HEPATITIS (HEPATOCELLULAR NECROSIS), DIFFUSE" SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | American Journal of Gastroenterology. Vol. 93, Pg. 459, 1998. |
mouse | LD50 | intravenous | 393mg/kg (393mg/kg) | BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | "Proceedings of the International Congress of Chemotherapy, 13th, Vienna, 1983," Spitzy, K.H. and K. Karrer, eds., 18 vols., Vienna, Austria, Verlag H. Egermann, 1983Vol. 6, Pg. 116/52, 1983. |
mouse | LD50 | oral | 4gm/kg (4000mg/kg) | Drugs of the Future. Vol. 9, Pg. 427, 1984. | |
rat | LD50 | intravenous | 213mg/kg (213mg/kg) | LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: ATAXIA BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | "Proceedings of the International Congress of Chemotherapy, 13th, Vienna, 1983," Spitzy, K.H. and K. Karrer, eds., 18 vols., Vienna, Austria, Verlag H. Egermann, 1983Vol. 6, Pg. 116/52, 1983. |
rat | LD50 | oral | 4gm/kg (4000mg/kg) | Drugs of the Future. Vol. 9, Pg. 427, 1984. | |
women | TDLo | oral | 200mg/kg/40D- (200mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" BEHAVIORAL: ANOREXIA (HUMAN LIVER: "JAUNDICE, CHOLESTATIC" | Journal of Hepathology. Vol. 24, Pg. 753, 1996. |
women | TDLo | oral | 210mg/kg/6W-I (210mg/kg) | SENSE ORGANS AND SPECIAL SENSES: CHANGE IN FUNCTION: TASTE | Lancet. Vol. 340, Pg. 728, 1992. |